Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core High Dividend ETF (HDV) vs Novavax Inc (NVAX) Price & Performance

iShares Core High Dividend ETFTrade
Novavax IncTrade

Price performance (Past 24H)

Key statistics

iShares Core High Dividend ETF vs Novavax Inc — how do they compare? iShares Core High Dividend ETF trades at $29.04, while Novavax Inc trades at $7.97 (market cap $1.31B). The key difference: iShares Core High Dividend ETF is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals.

HDVNVAX
52-Week High
$29.14$11.19
52-Week Low
$23.64$6.22
Market Cap
$1.31B
Sector
Health
Enterprise Value
$889.30M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core High Dividend ETF

HDV trades at $28.92, down 0.24% on the day, with a bullish technical signal supported by moving averages. The ETF focuses on high-quality dividend stocks, offering a 3.1% yield and outperforming the S&P 500 year-to-date by 9 percentage points according to 24/7 Wall Street on July 23, 2026. Recent institutional buying includes Bay Colony Advisory Group increasing its position by 370.7% in Q2 2026.

The outlook remains positive for income investors seeking stable dividends from large-cap US companies. Key risks include interest rate sensitivity and sector concentration in defensive stocks. Institutional accumulation and strong technical momentum support continued investor interest in this dividend-focused ETF.

Novavax Inc

Novavax (NVAX) trades at $7.97, up 1.01% with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported strong Q2 2026 results, beating revenue and earnings estimates while raising full-year guidance. Despite negative profitability metrics, valuation ratios appear attractive with P/E of 3.14 and EV/EBITDA of 1.72. Recent news highlights progress with Sanofi partnership and cost reduction initiatives.

The outlook remains challenged by negative cash flows and accumulated deficits, but analyst sentiment is positive with 74% buy ratings. Key risks include ongoing operational losses and vaccine demand volatility, while potential upside exists from partnership milestones and adjuvant platform expansion. The stock presents a high-risk opportunity with significant analyst support despite fundamental weaknesses.

Returns comparison

Trailing returns across standard periods

About iShares Core High Dividend ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.

Read more on HDV

About Novavax Inc

Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.

Read more on NVAX